Patents by Inventor Ferenc Soti
Ferenc Soti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9440948Abstract: Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2?substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2, compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2?substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.Type: GrantFiled: September 2, 2011Date of Patent: September 13, 2016Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: William Reade Kem, Ferenc Soti, Anne Rouchaud, Hong Xing, Jon Lindstrom, Kristin Marie Andrud
-
Patent number: 9233109Abstract: Briefly described, embodiments of this disclosure, among others, include compositions, pharmaceutical compositions, methods of treating nicotine dependence, methods of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorder, method of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorders, and the like.Type: GrantFiled: April 22, 2011Date of Patent: January 12, 2016Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Roger Lee Papke, Adriaan Willem Bruijnzeel, Sara Jo Nixon, William Kem, Ferenc Soti
-
Patent number: 9150558Abstract: The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward ?7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to ?7 nAChRs.Type: GrantFiled: December 11, 2012Date of Patent: October 6, 2015Assignee: University of Florida Research Foundation, Inc.Inventors: William R. Kem, Ferenc Soti, Hong Xing
-
Publication number: 20140343042Abstract: The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward ?7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to ?7 nAChRs.Type: ApplicationFiled: December 11, 2012Publication date: November 20, 2014Inventors: William R. Kem, Ferenc Soti, Hong Xing
-
Patent number: 8592458Abstract: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.Type: GrantFiled: December 16, 2011Date of Patent: November 26, 2013Assignee: University of Florida Research Foundation, Inc.Inventors: William Reade Kem, Ferenc Soti
-
Publication number: 20130157995Abstract: Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2?substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2, compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2?substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.Type: ApplicationFiled: September 2, 2011Publication date: June 20, 2013Inventors: William Reade Kem, Ferenc Soti, Anne Rouchaud, Hong Xing, Jon Lindstrom, Kristin Marie Andrud
-
Publication number: 20130137697Abstract: Briefly described, embodiments of this disclosure, among others, include compositions, pharmaceutical compositions, methods of treating nicotine dependence, methods of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorder, method of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorders, and the like.Type: ApplicationFiled: April 22, 2011Publication date: May 30, 2013Inventors: Roger Lee Papke, Adriaan Willem Bruijnzeel, Sara Jo Nixon, William Kem, Ferenc Soti
-
Publication number: 20120237563Abstract: The subject invention pertains to controlled-release dosage forms of anabaseine compounds, such as 3-(2,4-dimethoxybenzylidene)-anabaseine (also known as DMXBA or GTS-21) or a pharmaceutically acceptable salt thereof, methods of use, and methods for producing controlled-release dosage forms.Type: ApplicationFiled: August 18, 2010Publication date: September 20, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: William Reade Kem, Ferenc Soti, Robert Freedman, Lynn Johnson
-
Publication number: 20120094943Abstract: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.Type: ApplicationFiled: December 16, 2011Publication date: April 19, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: William R. Kem, Ferenc Soti
-
Patent number: 8093269Abstract: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.Type: GrantFiled: June 7, 2006Date of Patent: January 10, 2012Assignee: University of Florida Research FoundationInventors: William R. Kem, Ferenc Soti
-
Publication number: 20090215705Abstract: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.Type: ApplicationFiled: June 7, 2006Publication date: August 27, 2009Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: William R. Kem, Ferenc Soti
-
Patent number: 7307171Abstract: The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellents and selective inhibitors for aquatic and/or terrestrial crustacean pests.Type: GrantFiled: December 17, 2004Date of Patent: December 11, 2007Assignees: University of Florida, Duke UniversityInventors: William Reade Kem, Ferenc Soti, Dan Rittschof
-
Patent number: 7087106Abstract: The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellants and selective inhibitors for aquatic and/or terrestrial crustacean pests.Type: GrantFiled: February 19, 2004Date of Patent: August 8, 2006Assignees: University of Florida, Duke UniversityInventors: William Reade Kem, Ferenc Soti, Dan Rittschof
-
Publication number: 20050159454Abstract: The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellants and selective inhibitors for aquatic and/or terrestrial crustacean pests.Type: ApplicationFiled: December 17, 2004Publication date: July 21, 2005Inventors: William Kem, Ferenc Soti, Dan Rittschof
-
Publication number: 20040235901Abstract: The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellants and selective inhibitors for aquatic and/or terrestrial crustacean pests.Type: ApplicationFiled: February 19, 2004Publication date: November 25, 2004Inventors: William Reade Kem, Ferenc Soti, Dan Rittschof
-
Patent number: 5510345Abstract: The invention relates to novel eburnamenine derivatives of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 as well as R.sup.3 and R.sup.4, independently from each other, stand for hydrogen, C.sub.2-6 alkyl group, C.sub.2-6 alkenyl group; or a C.sub.3-10 alicyclic group involving 1 to 3 rings, and this latter group may be substituted by a C.sub.1-6 alkyl or C.sub.2-6 alkenyl group; or R.sup.1 and R.sup.2 and/or R.sup.3 and R.sup.4, together with the adjacent nitrogen atom and optionally with an additional oxygen or nitrogen atom, form a 4- to 6-membered, saturated or unsaturated cyclic group which may be substituted by a C.sub.1-6 alkyl or C.sub.2-6 alkenyl group; two of X, Y and Z are nitrogen whereas the third of them means a methine group; n is 1 or 2; W means oxygen or two hydrogen atoms; and the wavy line means .alpha.-/.alpha.-, .alpha.-/.beta.- or .beta.-/.alpha.- steric position, as well as their acid addition salts and solvates.Type: GrantFiled: December 8, 1994Date of Patent: April 23, 1996Assignee: Richter Gedeon Vegyeszeti Gyar Rt.Inventors: Zoltan Tuba, Sandor Maho, Aniko Gere, Pal Vittay, Bela Kiss, Eva Palosi, Laszlo Szporny, Csaba Szantay, Ferenc Soti, Zsuzsa Baloghne Kardos, Maria Incze, Gabor Balogh, Maria Gazdag
-
Patent number: 4843080Abstract: The invention relates to new racemic and optically active 1,12b-disubstituted octahydroindolo[2,3-a]quinolizine derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and represent hydrogen, halogen, nitro, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms or hydroxyl,R.sup.3 and R.sup.5 are the same or different and represent hydrogen, alkyl having from 1 to 6 carbon atoms or aralkyl having from 1 to 6 carbon atoms in the alkyl moiety,R.sup.4 is alkyl having from 1 to 6 carbon atoms, aryl or aralkyl having from 1 to 6 carbon atoms in the alkyl moiety, andR.sup.6 is an electron attracting substitutent, and cis and trans isomers and acid addition salts thereof.The compounds are pharmaceutically active, in particular show an outstanding cardiovascular, e.g. selective peripheral vasodilating activity. Some of these compounds are valuable intermediates in the preparation of other, pharmaceutically active compounds.Type: GrantFiled: April 17, 1986Date of Patent: June 27, 1989Assignee: Richter Gedeon Vegyeszeti Gyar Rt.Inventors: Csaba Szantay, Ferenc Soti, Maria Incze, Zsuzsanna Balogh nee Kardos, Zsolt Szombathelyi, Egon Karpati, Bela Kiss, Katalin Csomor, Istvan Laszlovszky, Erzsebet Lapis, Lilla Forgacs, Csaba Kuthi, Laszlo Szporny
-
Patent number: 4782052Abstract: The invention relates to new 1,2,3,4,6,7,12,12b-octahydroindolo[2,3,-a]quinolizin-1-yl-alkanecarboxylic acid amides of the formula (I), ##STR1## wherein R.sub.1 and R.sub.2 stand independently for a hydrogen or halogen atom, or a hydroxyl, nitro or C.sub.1-4 alkoxy group;R.sub.3 and R.sub.4 stand independently for a hydrogen atom or a C.sub.1-4 alkyl group;R.sub.5 and R.sub.6 stand independently for a hydrogen atom, C.sub.1-8 alkyl group, C.sub.3-8 alkenyl or cycloalkyl group, aryl or aralkyl group, heteroaryl or heteroaralkyl group containing oxygen, nitrogen or sulphur atom, all these groups being optionally substituted; orR.sub.5 and R.sub.6 together form an optionally substituted C.sub.2-8 .alpha.,.omega.-alkylene group, wherein one carbon atom may optionally be replaced by an oxygen or nitrogen atom; andG means a C.sub.1-4 straight chained alkylene group, as well as to their therapeutically suitable acid addition salts and pharmaceutical compositions containing these compounds.Type: GrantFiled: October 3, 1985Date of Patent: November 1, 1988Assignee: Richter Gedeon Vegyeszeti Gyar Rt.Inventors: Ferenc Soti, Csaba Szantay, Maria Incze, Zsuzsanna Balogh nee Kardos, Elemer Ezer, Judit Matuz, Laszlo Szporny, Gyorgy Hajos, Csaba Kuthi